Drug Profile
Relacorilant - Corcept Therapeutics
Alternative Names: CORT-125134Latest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Class Antineoplastics; Fluorine compounds; Isoquinolines; Ketones; Organic sulfur compounds; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cushing syndrome; Ovarian cancer; Pancreatic cancer
- Phase II Fallopian tube cancer; Peritoneal cancer; Prostate cancer
- Phase I/II Solid tumours
- No development reported Adrenocortical carcinoma
Most Recent Events
- 12 Jan 2024 Corcept Therapeutics completes a phase I clinical trial in Adenocarcinoma (Combination therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease) in USA (PO) (NCT04373265)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Adrenocortical-carcinoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Capsule)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Capsule)